相关专题 总有一种转染方法适合你

近日，罗氏公司新推出了两款高性能的DNA转染 试剂，为其细胞分析产品线再添新军。这两款名为X-tremeGENE 9和X-tremeGENE HP的转染试剂沿用了X-tremeGENE siRNA转染试剂的前缀，应该与大名鼎鼎的Fugene 6不属于一类。据罗氏介绍，这两个产品是多组分的独特试剂，并非脂质体。它们能够提供高的转染效率、重复性和细胞存活率。

这两款新产品都融合了罗氏二十年在转染 试剂上的经验。X-tremeGENE 9试剂为多种常用的细胞系带来了高效的性能，而X-tremeGENE HP试剂则更适合于难转染的细胞，比如原代细胞、昆虫细胞。如果您正在用其他试剂转染，但效果不佳，那么不妨试试这个。

两种试剂盒都综合了低的细胞毒性和高的转染 效率，让更多细胞存活，且带来生理上更相关的结果。而且，转染步骤也相当简单：只需用无血清培养基稀释转染试剂，与质粒共同孵育，然后逐滴加入细胞中。研究人员所需的优化极少，当然，在转染之前，你还是得优化转染试剂与DNA的比例。建议的比例是3:1，但对于特定研究，2:1至7:1的比例可能会提高转染效率。

此外，X-tremeGENE HP试剂还经过0.2 μm孔径的膜过滤，无动物来源成分，在血清中也有活性。它与核酸形成复合物，促进高效的DNA转移，而带来的生理和形态学改变极少。它非常适合细胞分析和蛋白表达 研究。

至于这两种试剂的选择，请看下表。如果转染 HeLa、HEK-293等普通细胞系，这两个都能胜任。至于那些难搞定的细胞，则最好选择X-tremeGENE HP试剂。若说到试剂的温和性，恐怕X-tremeGENE 9试剂要更胜一筹。

至于细胞系特异的转染步骤，罗氏网站上也列出了一些，估计还会不断补充。目前X-tremeGENE HP有以下细胞的具体步骤：High Five、Sf9、HT-1080、K-562、MEF、PC-12等等。X-tremeGENE 9则有293、CHO、COS-7、Hela等等。详细步骤请浏览罗氏的网站或查询在线数据库。

大家肯定很感兴趣这两种新试剂与Fugene的对比，但小编手头找不到相关数据，自然也不能妄下推断。如果以后有了相关资料，再补充上来。也欢迎各位吃螃蟹的童鞋发表一下使用感言。

原文摘要：

Penzberg, Germany, December 6, 2010

Roche introduces new X-tremeGENE DNA transfection reagents with high efficiency and reproducibility, low cytotoxicity

Two new high-performance reagents deliver more viable cells, help accelerate cellular and molecular research efforts

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research. Designed for commonly used and hard-to-transfect cell lines, the X-tremeGENE 9 and X-tremeGENE HP reagents offer high efficiency, reproducibility and cell survival rates, compared to leading transfection reagents, to deliver more viable cells and help accelerate research efforts. Both reagents support a wide variety of cellular and molecular research applications, such as gene expression analysis and protein production.

The two new products build on Roche’s 20 years of experience with transfection reagents. The X-tremeGENE 9 reagent offers efficient performance across a wide variety of commonly used cell lines while Roche’s X-tremeGENE HP reagent is especially well suited for cell lines that are difficult to transfect or not easily transfected with other reagents.

Both reagents combine low cytotoxicity with high efficiency and reproducibility, providing more viable cells with more physiologically relevant results. They also offer easy-to-implement protocols: Researchers simply dilute the reagent, incubate it with plasmid DNA, and pipette it directly onto cells. The simple process enables researchers to spend less time optimizing the reagent and more time advancing their research.

Both reagents function well in the presence or absence of serum and remain stable after repeated vial openings, helping to save researchers time and effort. More information is available at www.x-tremegene.roche.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

X-tremeGENE is a trademark of Roche.

Other brands or product names are trademarks of their respective holders.